Description
| Description | Tapinarof is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease. |
| Targets&IC50 | AhR:13 nM（EC50） |
| In vitro | Tapinarof activates the AhR pathway through direct binding. Tapinarof induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) in a dose-dependent way. |
| In vivo | Tapinarof acts through AhR to reduce inflammation in IMQ-treated mice. AhR-sufficient mice on a C57Bl/6 background exhibit a reduced clinical score after treatment with Tapinarof or 6-formylindolo(3,2-b)carbazole (FICZ). On the contrary, AhR KO mice do not respond to the anti-inflammatory effects of Tapinarof. FICZ is used as a comparator in these studies and yields similar results, with dramatically reduced inflammatory responses in wild-type, but not AhR KO mice. |
| Synonyms | GSK2894512, Benvitimod, WBI 1001 |
| Molecular Weight |
254.32 |
| Formula | C17H18O2 |
| CAS No. | 79338-84-4 |
Storage
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Solubility Information
DMSO: 150 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
